GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070202 | Oral cavity | EOLP | microtubule nucleation | 14/2218 | 35/18723 | 2.11e-05 | 3.28e-04 | 14 |
GO:005160721 | Oral cavity | EOLP | defense response to virus | 55/2218 | 265/18723 | 2.16e-05 | 3.35e-04 | 55 |
GO:014054621 | Oral cavity | EOLP | defense response to symbiont | 55/2218 | 265/18723 | 2.16e-05 | 3.35e-04 | 55 |
GO:006099614 | Oral cavity | EOLP | dendritic spine development | 27/2218 | 99/18723 | 2.21e-05 | 3.37e-04 | 27 |
GO:000222411 | Oral cavity | EOLP | toll-like receptor signaling pathway | 31/2218 | 121/18723 | 2.21e-05 | 3.37e-04 | 31 |
GO:003812723 | Oral cavity | EOLP | ERBB signaling pathway | 31/2218 | 121/18723 | 2.21e-05 | 3.37e-04 | 31 |
GO:009730525 | Oral cavity | EOLP | response to alcohol | 53/2218 | 253/18723 | 2.31e-05 | 3.50e-04 | 53 |
GO:00026968 | Oral cavity | EOLP | positive regulation of leukocyte activation | 77/2218 | 409/18723 | 2.34e-05 | 3.52e-04 | 77 |
GO:009728413 | Oral cavity | EOLP | hepatocyte apoptotic process | 9/2218 | 16/18723 | 2.37e-05 | 3.55e-04 | 9 |
GO:001820521 | Oral cavity | EOLP | peptidyl-lysine modification | 72/2218 | 376/18723 | 2.38e-05 | 3.56e-04 | 72 |
GO:005087014 | Oral cavity | EOLP | positive regulation of T cell activation | 47/2218 | 216/18723 | 2.40e-05 | 3.58e-04 | 47 |
GO:000926721 | Oral cavity | EOLP | cellular response to starvation | 37/2218 | 156/18723 | 2.44e-05 | 3.62e-04 | 37 |
GO:006220713 | Oral cavity | EOLP | regulation of pattern recognition receptor signaling pathway | 28/2218 | 105/18723 | 2.46e-05 | 3.65e-04 | 28 |
GO:000854424 | Oral cavity | EOLP | epidermis development | 64/2218 | 324/18723 | 2.48e-05 | 3.68e-04 | 64 |
GO:004561912 | Oral cavity | EOLP | regulation of lymphocyte differentiation | 40/2218 | 174/18723 | 2.54e-05 | 3.75e-04 | 40 |
GO:004312322 | Oral cavity | EOLP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 42/2218 | 186/18723 | 2.54e-05 | 3.75e-04 | 42 |
GO:004580724 | Oral cavity | EOLP | positive regulation of endocytosis | 27/2218 | 100/18723 | 2.69e-05 | 3.94e-04 | 27 |
GO:000703014 | Oral cavity | EOLP | Golgi organization | 37/2218 | 157/18723 | 2.83e-05 | 4.12e-04 | 37 |
GO:004209817 | Oral cavity | EOLP | T cell proliferation | 44/2218 | 199/18723 | 2.86e-05 | 4.14e-04 | 44 |
GO:199082315 | Oral cavity | EOLP | response to leukemia inhibitory factor | 26/2218 | 95/18723 | 2.91e-05 | 4.20e-04 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |